Thus, TC1 and C3PQ cell lines were treated with SKI-G-801, an AXL inhibitor, to investigate the efficacy of a chemo- and immunotherapy in order to prove potential effects of AXL inhibitor on therapeutic strategy and anti-tumor activity on LUSC and LUAD through a model-based analysis. This evidence concerns the gene AXL and neoplasm.